1. Analyst View
2. Research Methodology
3. Global Cancer Drugs Market Outlook 2018
3.1 Cancer Incidences
3.2 Cancer Drug Market
4. Global Cancer Generics Market Analysis 2018
5. Cancer Generic Drugs Industry
5.1 Oral Generic Drugs
5.1.1 Arimidex (Anastrozole)
5.1.2 Femara (Letrozole)
5.1.3 Hycamtin (Topotecan)
5.1.4 Stivarga (Regorafenib)
5.1.5 Tarceva (Erlotinib)
5.1.6 Xalkori (Crizotinib)
5.1.7 Xeloda (Capecitabine)
5.2 Generic Injectables
5.2.1 Camptosar (Irinotecan Hydrochloride)
5.2.2 Eloxatin (Oxaliplatin)
5.2.3 Gemzar (Gemcitabine Hydrochloride)
5.2.4 Navelbine (Vinorelbine Tartrate)
5.2.5 Platinol (Cisplatin)
5.2.6 Taxol (Paclitaxel)
5.2.7 Taxotere (Docetaxel)
6. Cancer Generics Market: Major Indications
6.1 Lung Cancer
6.1.1 Incidence Outlook
6.1.2 Commercialized Drugs
6.2 Breast Cancer
6.2.1 Incidence Outlook
6.2.2 Commercialized Drugs
6.3 Colorectal Cancer
6.3.1 Incidence Outlook
6.3.2 Commercialized Drugs
6.4 Stomach Cancer
6.4.1 Incidence Outlook
6.4.2 Commercialized Drugs
6.5 Prostate Cancer
6.5.1 Incidence Outlook
6.5.2 Commercialized Drugs
7. Market Dynamics
7.1 Indian Generic Cancer Drug Introduced in the US Market
7.2 Launch of Generic Drugs for Oncology
7.3 Increasing Cancer Burden Paving Way for Generics
7.4 Patent Expiry of Blockbuster Oncology Drugs
7.5 Strategic Collaborations
8. Key Players
8.1 Fresenius Kabi AG
8.1.1 Business Overview
8.1.2 Key Financials
8.1.3 Strategic Developments
8.2 Actavis Plc.
8.2.1 Business Overview
8.2.2 Key Financials
8.2.3 Strategic Developments
8.3 Hospira
8.3.1 Business Overview
8.3.2 Key Financials
8.3.3 Strategic Developments
8.4 Teva Pharmaceutical Industries Ltd.
8.4.1 Business Overview
8.4.2 Key Financials
8.4.3 Strategic Developments
8.5 Mylan
8.5.1 Business Overview
8.5.2 Key Financials
8.5.3 Strategic Developments
8.6 Sun Pharmaceuticals
8.6.1 Business Overview
8.6.2 Key Financials
8.6.3 Strategic Developments